NIH and Other Independent Studies Confirm Low Levels of BioAegis’ ‘Inflammation Regulator Protein,’ Gelsolin, Associated with COVID-19 Severity
February 02, 2021 14:05 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
New book provides a simple solution to conquer inflammation, the underlying cause of the majority of the disease today
January 18, 2021 18:00 ET
|
Balboa Press
SAN DIEGO, Jan. 18, 2021 (GLOBE NEWSWIRE) -- As a cancer survivor who has experienced the devastating effects of cancer, Dr. Bruce Howe made it his mission to research the subject of inflammation...
Specialized Pro-Resolving Mediators (SPMs) Shown to Resolve Inflammation and Improve Infection Clearance
January 13, 2021 10:15 ET
|
Life Extension
Fort Lauderdale, FL, Jan. 13, 2021 (GLOBE NEWSWIRE) -- A recent review article describes how compounds called specialized pro-resolving mediators (SPMs) may be a viable treatment for inflammatory...
Juva Life Introduces Advisory Team in Preparation for Advancement Towards “Precision Cannabis”
December 08, 2020 04:30 ET
|
Juva Life Inc.
VANCOUVER, British Columbia, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a premier California based...
US Capital Global Securities Launches $10MM Convertible Preferred Stock Offering for Cardax, Inc.
November 24, 2020 16:58 ET
|
US Capital Global
San Francisco, California, Nov. 24, 2020 (GLOBE NEWSWIRE) -- US Capital Global Securities LLC, an affiliate of US Capital Global, is offering to eligible investors an investment opportunity of up to...
Enosi Life Sciences Files Patent for TNF-Inhibiting Molecules EN1001, EN2001 and EN3001
November 18, 2020 09:00 ET
|
Enosi Life Sciences
SAN DIEGO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Enosi Life Sciences Corp. (“Enosi” or the “Company”), a drug research and development company focused on providing industry-leading therapeutics for...
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders
November 17, 2020 08:00 ET
|
180 Life Sciences Corp.
MENLO PARK, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused...
BioAegis Therapeutics Expands Phase 2 COVID-19 Treatment Clinical Trial in EU for Inflammation Regulator
November 15, 2020 19:35 ET
|
BioAegis Therapeutics
No drug-related safety signals identified by the independent Data and Safety Monitoring Board.MORRISTOWN, N.J., Nov. 15, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage,...
Groundbreaking Studies Offer Hope for Unmet Medical Needs in Inflammatory Disease
October 01, 2020 08:30 ET
|
180 Life Sciences Corp.
NEW YORK, Oct. 01, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsWire -- 180 Life Sciences Corp. (NASDAQ: KBLM) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of...
BioAegis Therapeutics Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia
September 03, 2020 21:42 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...